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Cardiac hypertrophy, initially an adaptive response of the myo-
cardium to stress, can progress to heart failure. The epigenetic
signature underlying this phenomenon is poorly understood. Here,
we report on the genome-wide distribution of seven histone mod-
iﬁcations in adult mouse cardiomyocytes subjected to a prohyper-
trophy stimulus in vivo. We found a set of promoters with an
epigenetic pattern that distinguishes speciﬁc functional classes
of genes regulated in hypertrophy and identiﬁed 9,207 candidate
active enhancers whose activity was modulated. We also analyzed
the transcriptional network within which these genetic elements
act to orchestrate hypertrophy gene expression, ﬁnding a role
for myocyte enhancer factor (MEF)2C and MEF2A in regulating
enhancers. We propose that the epigenetic landscape is a key
determinant of gene expression reprogramming in cardiac hy-
pertrophy and provide a basis for understanding the role of
chromatin in regulating this phenomenon.
epigenetic regulation | histone acetylation | histone methylation
Heart failure, a leading cause of mortality worldwide, is fre-quently accompanied by cardiac hypertrophy, a process
characterized by the expression of genes normally present during
the fetal stage and the repression of certain genes expressed in
adults (1, 2). Although epigenetics is important in regulating
transcription, our understanding of its role in cardiac hypertro-
phy remains scant (3).
Histone marks, such as acetylation (ac) and methylation (me)
of lysine (K) residues of histone H3, play an important role in
regulating transcription. Combinations of these marks create an
“epigenetic code” that deﬁnes the transcriptional status of genes:
high levels of monoacetylated (ac) Lys-9 and Lys-14 (H3K9ac
and H3K14ac) and trimethylated (me3) Lys-4 (H3K4me3) in
promoter regions, and trimethylated Lys-36 (H3K36me3) and di-
methylated (me2) Lys-79 (H3K79me2) in the body of genes, are
detected in transcriptionally active regions. In contrast, an ele-
vated level of deacetylated histones and histone H3 trimethy-
lated on Lys-9 and Lys-27 (H3K9me3 and H3K27me3) are
associated with inactive regions (4–7).
Histone modiﬁcations also inﬂuence the activity of enhancers
involved in regulating gene expression during development and
cell differentiation. In human embryonic stem cells, speciﬁc
epigenetic signatures deﬁne the activity of enhancer elements
involved in the early stages of embryogenesis: H3K27ac is a
mark of active (or class 1) enhancers, whereas a high level of
H3K27me3 and the absence of H3K27ac are found in “poised”
(or class 2) enhancers (8). The acetyltransferase and transcrip-
tional coactivator p300/CBP binds active enhancers in several
tissues and organs, including heart, during development (9).
Recently, a large set of enhancer elements involved in regulating
cardiomyocyte gene expression during differentiation in vitro
was identiﬁed (10).
Hitherto, most research on the epigenetics of heart failure has
focused on the role of histone deacetylases (HDACs; e.g., HDAC5,
HDAC9, and HDAC2) and histone acetyl transferases (HATs;
e.g., p300). These studies demonstrated a key role for these
enzymes in the cardiac hypertrophy program and, thus, suggest a
role for histone acetylation in triggering the transcriptional changes
occurring in cardiac hypertrophy and heart failure (11–14). How-
ever, we still do not know which genes are regulated by histone
modiﬁcations or how histone modiﬁcations inﬂuence transcrip-
tion in cardiac hypertrophy.
Here, we describe epigenetic changes occurring in adult
mouse cardiomyocytes subjected to a prohypertrophy stimulus
in vivo.
Results
Epigenetic Proﬁle Changes in Hypertrophic Cardiomyocytes. To gain
insight into the role epigenetics plays in heart failure, we gen-
erated genome-wide chromatin-state maps for normal and hy-
pertrophic cardiomyocytes and compared them with the gene
expression proﬁles of those cells (Fig. 1A). To this end, we
performed chromatin immunoprecipitation (ChIP) coupled with
massively parallel DNA sequencing (ChIP-seq) on cardiomyocytes
isolated from the left ventricle of mice that had been subjected
to transverse aortic constriction (TAC), a surgical procedure that
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induces cardiac hypertrophy and then heart failure. Cardiomyocytes
were isolated 1 wk after TAC, a time corresponding to the
maximal activation of compensatory cardiac mechanisms (15,
16). The purity of isolated cardiomyocytes was at least 95%,
as evaluated by counting the number of cells with and without
the typical rod-shaped appearance (Fig. S1A). ChIP-seq was per-
formed using antibodies against H3K9ac, H3K27ac, and H3K4me3,
three marks associated with active regulatory regions; H3K79me2,
a mark associated preferentially with transcribed genes (17); and
H3K9me2, H3K9me3, and H3K27me3, which are associated with
repressed regions (4–7).
To identify the genomic regions undergoing a change of their
histone mark proﬁle on cardiac hypertrophy, we used two algo-
rithms, MACS (model-based analysis of ChIP-seq) (18) and SICER
(spatial clustering approach for the identiﬁcation of ChIP-enriched
regions) (19), to minimize the bias inherent in this procedure and
compared the obtained peak datasets with DiffBind (differential
binding analysis of ChIP-seq peak data) (20). Hierarchical clus-
tering analysis using afﬁnity (read count) data revealed that the
histone marks studied were signiﬁcantly redistributed during
cardiac hypertrophy (Fig. 1B). This result was supported by MA
[M(log ratios)A(mean average)] plots, which evidenced the high
number of differential histone modiﬁcation sites in sham versus
TAC cardiomyocytes (Fig. S1B and Dataset S1). We found that
9.1% of the genome of hypertrophic cardiomyocytes had
a change in the distribution of at least a single histone mark (Fig.
S1C), with all histone marks analyzed becoming redistributed to
transcription start sites (TSSs) (±4 kb) (Fig. S2A).
To obtain information on the biological role of genomic
regions found with redistributed histone marks, we performed
gene ontology (GO) analysis with the Genomic Regions En-
richment of Annotations Tool (21) (GREAT; default setting, 5 +
1 kb basal, up to 1 Mb extension) (Fig. S2B). The sites with
differential distribution of H3K9ac, H3K27ac, or H3K4me3
mapped preferentially to regulatory domains of genes involved in
heart function or epigenetic regulation of gene expression,
whereas those with altered H3K79me2, H3K9me2, H3K9me3, or
H3K27me3 proﬁles were preferentially associated with genes
regulating signal transduction (e.g., regulation of Rab-GTPase
activity and regulation of ARF GTPase activity) and organiza-
tion and regulation of sarcomeric structure. Moreover, GO
analysis for mouse phenotype revealed that sites with differential
distribution of H3K9ac, H3K4me3, H3K79me2, or H3K27me3
were associated with hypertrophic heart phenotypes, such as
thick ventricular wall, altered heart contraction, impaired skel-
etal muscle contractility, and abnormal cardiac stroke volume.
Together, these ﬁndings demonstrate that pressure-overload
hypertrophy is associated with major chromatin remodeling of
a wide array of genes regulating cardiac function.
Histone Modiﬁcations Regulate the Promoter Activity of Genes
Modulated by Pressure Overload. Next, we determined whether
this chromatin remodeling was responsible for regulating the
gene expression changes associated with cardiac hypertrophy. To
this end, we ﬁrst performed RNA sequencing (RNA-seq) on
polyadenylated RNA extracted from cardiomyocytes isolated
Fig. 1. Genome-wide analysis of histone marks in adult cardiomyocytes isolated from pressure-overloaded and control mouse hearts. (A) Schematic of the
experimental workﬂow. (B) Hierarchical clustering of H3K9ac (9ac), H3K27ac (27ac), H3K4me3 (4me3), H3K79me2 (79me2), H3K9me2 (9me2), H3K9me3
(9me3), and H3K27me3 (27me3) on the basis of their genomic distribution in normal (sham) and hypertrophic (TAC) cardiomyocytes. The heat map was
generated with the DiffBind program. Also see Fig. S1B and Dataset S1.
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from the same mouse hearts used for epigenetic proﬁling. We
identiﬁed 1,109 genes differentially expressed with a log-fold
change in expression ≥1.3 in TAC cardiomyocytes (adjusted
P value < 0.05); of these, 65.46% (726 genes) were up-regulated
and 34.53% (383 genes) were down-regulated (Fig. S3 A and B
and Dataset S2).
We then examined the transcriptional level of those genes that
had undergone a change at their promoter region (i.e., ±2 kb
around the TSS) in only one of the seven histone marks (Fig.
S3C). We found that a decrease in H3K9ac or H3K27ac was
signiﬁcantly associated with transcription repression in TAC
cardiomyocytes; conversely, a decrease in either H3K9me3 or
H3K27me3 was associated with genes that were more actively
transcribed. Moreover, either a loss or a gain of H3K79me2 at
promoters could be associated with more-expressed genes in
TAC cardiomyocytes. Because H3K79me2 distributes to the
body of genes as well as promoters, we also analyzed the re-
lationship between gene expression and changes in the distribution
of this histonemark at the former region (Fig. S3C). Consistent with
previous reports (6, 22), an increase of H3K79me2 at gene bodies
correlated signiﬁcantly with a more-expressed gene set.
Quantitatively, of the 1,109 genes modulated in TAC car-
diomyocytes, we found that 596 genes had an alteration of at
least one histone mark at their promoter. Three hundred twenty-
ﬁve (29.30%) of these genes had a transcriptional level and an
epigenetic landscape consistent with the epigenetic code theory
(23) for the seven histone marks studied. One-way hierarchi-
cal clustering of the 325 genes on the basis of fold change in
expression revealed the presence of two main gene clusters
(Fig. 2A): one comprised 135 genes that were up-regulated in
TAC cardiomyocytes and that either gained activating marks
or lost repressor marks at their promoters, and the other
Fig. 2. Analysis of epigenetic changes occurring at the promoter of genes modulated in cardiac hypertrophy. (A) Heat map of the changes in the histone
mark proﬁles occurring at the promoters of 325 genes found modulated in TAC cardiomyocytes in accordance with the epigenetic code for the seven
modiﬁcations studied. The genes were ordered on the basis of fold change in expression. (B) Heat maps of hierarchical clustering of the 135 up-regulated
genes (Left) and the 190 down-regulated genes (Right) on the basis of the changes in expression of the histone marks. The diagrams below the heat maps give
schematic representations of the results. (C) Examples of the distribution of reads obtained by ChIP-seq and RNA-seq in ten loci related to cardiac hypertrophy
and heart development in sham and TAC cardiomyocytes. The distributions of the histone marks were normalized to input and library dimension. Uniform
scales are used for each histone mark and for mRNA. S, sham; T, TAC; 9ac, H3 monoacetylated at lysine 9; 79me2, H3 di-methylated at lysine 79; 9me3, H3
trimethylated at lysine 9; 27ac, H3 monoacetylated at lysine 27.
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contained 190 down-regulated genes having an epigenetic
proﬁle with an opposite trend to that of the ﬁrst cluster (i.e.,
increased repressor marks or decreased activator marks).
Moreover, histone pattern analysis of the two clusters revealed
that transcriptional activation in TAC cardiomyocytes was inﬂu-
enced to an equal extent by each of the seven histone marks,
whereas repression of gene expression was inﬂuenced more by
a decrease in H3K9ac or an increase in either H3K9me3 or
H3K27me3 than by changes in the other epigenetic mod-
iﬁcations (Fig. 2B). Notably, in both clusters, promoters pre-
senting with changes in activator marks did not have any
alteration of repressive ones, and vice versa, indicating that
these classes of histone marks regulate distinct genes in cardiac
hypertrophy. GO analysis revealed that a signiﬁcant number of
the genes activated by the epigenetic modiﬁcations were im-
plicated in cell adhesion, cytoskeletal formation, and heart
development; in contrast, a signiﬁcant number of repressed
genes were involved in oxidative stress and gene transcription
regulation (Fig. S3D). Thus, histone H3 marks provide an
epigenetic signature that distinguishes genes regulated in car-
diac hypertrophy, including important players of this pathol-
ogy, such as Rgs2, Tcap, Bmp2, and Tgfbr1 (Fig. 2C). For some
of these cardiomyocyte-speciﬁc genes, we conﬁrmed the epi-
genetic changes with ChIP performed on total heart from mice
after 1 wk of TAC (Fig. S4).
Identiﬁcation of Active Enhancers Speciﬁc for Cardiac Hypertrophy.
The enhancers associated with hypertrophy are unknown. Be-
cause active enhancers can be distinguished by the presence of
H3K27ac (24, 25), we mined our ChIP-seq dataset to identify those
enhancers. We found 9,207 putative active enhancers mapping
to noncoding intra- and intergenic regions (Fig. S5A and Dataset
S2). This set of predicted enhancers overlaps 5.8% with p300/
CBP+ enhancers identiﬁed during heart development and 53.3%
with H3K4me1+/H3K27ac+ enhancers found associated with car-
diomyogenic differentiation (9, 10) (Fig. S5B).
Our set of H3K27ac+ enhancers was associated with genes
involved in cellular processes underlying cardiac hypertrophy,
such as metabolic process, gene expression, and cytoskeleton
organization (Fig. S5C). This ﬁnding was supported by GO of the
human phenotype, which revealed that genes associated with
these enhancers were involved in several cardiac disease states
(Fig. S5C). Moreover, an analysis of evolutionary conservation
of the enhancers revealed that, similar to what has already been
observed for cardiac enhancers associated with heart development
and cardiomyocyte differentiation (10, 26), these genetic elements
are poorly conserved in placental mammals and vertebrates
[phylogenetic analysis with space/time models conservation
(PhastCons) score, 12% and 9%, respectively]. However, we did
ﬁnd a large set of enhancers (1,560 elements) conserved in humans
and mice (Fig. S5D and SI Materials and Methods). Therefore, we
have brought to light a large number of hitherto undescribed pu-
tative enhancer elements speciﬁc to the cardiomyocyte and highly
conserved in man.
To determine whether these genetic elements regulate the
gene expression program of hypertrophy, we classiﬁed the en-
hancers on the basis of the presence/absence of H3K27ac and
H3K27me3. H3K27ac+ enhancers were deemed “active,” or
class 1, and H3K27me3+ enhancers were considered “poised,” or
class 2, whereas H3K27ac−/H3K27me3− enhancers were classed
as “intermediate” (8, 25). Consistent with this classiﬁcation, the
gene set associated with class 1 enhancers was expressed at
a level signiﬁcantly higher than that associated with intermediate
enhancers in both sham and TAC cardiomyocytes (Fig. S6A). Of
note, there were few enhancers (34 of 9,207) belonging to class 2.
With the induction of cardiac hypertrophy, a large fraction
of enhancers switched class (Fig. 3A). This phenomenon
was associated with a variation in the transcriptional level of
neighboring genes: The gene set associated with enhancers
switching from the intermediate class to class 1 had an increased
expression in TAC cardiomyocytes (Fig. 3B). This set included
markers of hypertrophy, such as Actn1, Hif1a, Fstl1, and Anxa2
(Fig. S6B). In contrast, genes associated with enhancers shifting
in the opposite direction were less expressed in hypertrophic car-
diomyocytes. This demonstrates that enhancers are involved in
promoting the expression of genes in hypertrophy through an
epigenetic signature that regulates their activity.
Finally, to identify the transcription network within which the
epigenetically regulated promoters and enhancers acted to gov-
ern gene expression in TAC cardiomyocytes, we searched for the
presence of transcription factor-binding motifs within these ge-
netic elements. Hypergeometric optimization of motif enrich-
ment (HOMER) (27) analysis revealed that motifs for myocyte
enhancer factor (MEF)2C and MEF2A were signiﬁcantly enriched
at enhancers, whereas motifs for speciﬁcity protein 1 (SP1),
nuclear factor Y (NFY), and kruppel-like factor 4 (KLF4) were
found at promoters (Fig. 4 A and B and Fig. S7A). To validate
these predictions, we performed ChIP for MEF2C and MEF2A
on cardiomyocytes isolated from sham and TAC mice. We found
that MEF2C and MEF2A bound to 56.5% of the enhancers
having binding motifs for these transcription factors and that
were associated with genes modulated in cardiac hypertrophy,
such as Grk5, Irs1, and Gpx3 (Fig. S7B). These results suggest
that MEF2C and MEF2A, the two transcription factors that
fundamentally promote gene expression in cardiac hypertrophy
(12, 28), regulate the activity of enhancers.
Fig. 3. Activity of enhancers in cardiac hypertrophy. (A) Distribution map
illustrating the shift occurring between class 1 and intermediated class
enhancers on induction of hypertrophy. Sham, cardiomyocytes in a basal
condition; TAC, cardiomyocytes isolated from mice subjected to pressure
overload. Enhancers with a peak score of MACS for H3K27ac higher than 50
were classiﬁed class 1, whereas enhancers with a peak score of less than 50
were classiﬁed as intermediate. (B) Box plots of gene expression values for
all genes (bars in gray shades) and those associated with enhancers that
change class on cardiac hypertrophy (yellow bar, intermediate class
enhancers changing into class 1; blue bar, class 1 enhancers changing into
intermediate class). Box plots represent interquartile ranges, with the bot-
tom and the top of the boxes indicating the 25th and 75th percentiles, re-
spectively; the internal bands correspond to the 50th percentile. P values
were determined by unpaired Wilcoxon test. *P < 0.01. RPKM, reads per kilo
base per million; Int., intermediate class; I, class 1.
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Discussion
In this study, we identiﬁed a speciﬁc epigenetic signature at
promoters and discovered enhancers acting as regulatory ele-
ments associated with cardiac hypertrophy. So far, research on
the epigenetics of heart failure has focused on histone acetyla-
tion mainly by means of mouse knockout models of genes
encoding HDACs and HATs (12, 29). The studies revealed a key
role of those enzymes in triggering gene expression changes in
cardiac hypertrophy. Moreover, the chromatin remodeling fac-
tors Brg1, HDAC, and poly (ADP-ribose) polymerase (PARP)
were demonstrated to cooperate in regulating gene expression of
α- and β-myosin heavy chains during cardiac hypertrophy (30).
However, little is still known about the genes regulated by his-
tone acetylation, and the role of histone methylation remains
largely uninvestigated. Indeed, although previous work has sug-
gested an involvement of histone methylation in cardiac hyper-
trophy (31, 32), those researchers did not provide evidence for
a role of this histone mark in regulating gene expression. Our
study reveals that a speciﬁc epigenetic signature, deﬁned by
histone acetylation and methylation, regulates gene expression of
hypertrophy by governing the activity of promoters. In fact, the
expression of a large set of genes (325 of 1,109 genes) is regulated
through a speciﬁc epigenetic signature. This signature is charac-
terized by the mutual exclusion of activating (H3K9ac, H3K27ac,
H3K4me3, andH3K79me2) and repressive (H3K9me2,H3K9me3,
and H3K27me3) histone marks. Thus, these activating and re-
pressive epigenetic modiﬁcations do not act cooperatively in reg-
ulating the activity of promoters but, instead, regulate distinct
gene sets.
It is noteworthy that not all genes showed epigenetic changes
consistent with epigenetic code theory. The expression of these
genes could be regulated by mechanisms that go beyond the
histone modiﬁcations studied in this work. These could include
mechanisms that inﬂuence the activity of transcription factors
(e.g., their expression, nuclear localization, activation by post-
translational modiﬁcations, presence of cofactors) and other
Fig. 4. Transcription networks of genes regulated epigenetically in cardiac hypertrophy. (A) The transcription binding motifs identiﬁed for promoters
regulated epigenetically in cardiac hypertrophy (Left) and for putative, active enhancers (Right). Also see SI Materials and Methods. (B) Predicted genes
regulated in cardiac hypertrophy through the binding of SP1, NFY, and KLF4 with promoters modulated epigenetically, and MEF2C and MEF2A with
enhancers (Right). The colors of the nodes represent fold change of expression in cardiac hypertrophy, as indicated by the scale. (C ) Model of how the
transcription factors could act in regulating the expression of genes affected epigenetically in cardiac hypertrophy. On the basis of this model, MEFs
govern the activity of enhancers, whereas SP1, NFY, and/or KLF4 affect the activity of promoters in triggering gene expression changes in cardiac hy-
pertrophy. MEF, myocyte enhancer factor; SP1, transacting transcription factor 1; NFY, nuclear transcription factor-Y; KLF4, Kruppel-like factor 4; HDAC,
histone deacetylase.
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epigenetic mechanisms that were not examined (e.g., DNA
methylation, long noncoding RNAs, other histone modiﬁcations).
In addition, we have identiﬁed more than 9,000 putative active
enhancers associated with cardiac hypertrophy. Surprisingly, the
identiﬁed enhancers are largely unrelated to those previously
described in heart development and cardiomyocyte differentia-
tion (9, 10). Our results support the notion that during cardiac
hypertrophy, the underlying gene expression reprogramming is
regulated both by enhancers involved in heart development and
by cis regulatory elements speciﬁcally active in this pathology
(Fig. 4 and Fig. S6). Moreover, transcription network analysis of
these genetic elements has revealed a role for MEF2C and
MEF2A in regulating the activity of enhancers.
Although our ﬁndings do not elucidate the molecular pathways
upstream of the histone marks, the fact that hypertrophy is asso-
ciated with altered epigenetic proﬁles at enhancers and promoters
does provide clues to the mechanisms regulating its pathogenesis.
Materials and Methods
For full details, see Transverse Aortic Constriction and Cardiomyocte Iso-
lation and Transcription Network Analysis. Brieﬂy, 2-mo-old male C57BL/
6J mice were subjected, under anesthesia, to TAC, as described previously
(33). All of the experiments were performed according to the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health (publication 85–23, revised 1996) and approved by the
local ethical committee of the Italian Ministry of Health. ChIP-seq and
RNA-seq were carried out as described previously (33–36). MACS (18) and
SICER (19) were used to identify the genomic regions bound to histones,
whereas DiffBind (20) was used to identify the differential histone mod-
iﬁcation sites between sham and TAC cardiomyocytes.
ACKNOWLEDGMENTS. We thank Rory Stark and Gordon Brown of Cancer
Research UK and the Cambridge Research Institute for help with data
analysis with DiffBind. This work was supported by an Advanced Grant
(CardioEpigen; 294609) from the European Research Council, grants from
Fondation LeDucq and Fondazione CARIPLO (12-4-5157157-31; to G.C.),
Grant EPIGEN (Progetto Bandiera Epigenomica), and Ageing Project (Pro-
getto Bandiera Invecchiamento; to R.P.).
1. Lompre AM, et al. (1979) Myosin isoenzyme redistribution in chronic heart overload.
Nature 282(5734):105–107.
2. Izumo S, Nadal-Ginard B, Mahdavi V (1988) Protooncogene induction and repro-
gramming of cardiac gene expression produced by pressure overload. Proc Natl Acad
Sci USA 85(2):339–343.
3. Papait R, Greco C, Kunderfranco P, Latronico MV, Condorelli G (2013) Epigenetics: A
new mechanism of regulation of heart failure? Basic Res Cardiol 108(4):361.
4. Barski A, et al. (2007) High-resolution proﬁling of histone methylations in the human
genome. Cell 129(4):823–837.
5. Steger DJ, et al. (2008) DOT1L/KMT4 recruitment and H3K79 methylation are ubiq-
uitously coupled with gene transcription in mammalian cells. Mol Cell Biol 28(8):
2825–2839.
6. Nguyen AT, Zhang Y (2011) The diverse functions of Dot1 and H3K79 methylation.
Genes Dev 25(13):1345–1358.
7. Ernst J, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human
cell types. Nature 473(7345):43–49.
8. Rada-Iglesias A, et al. (2011) A unique chromatin signature uncovers early devel-
opmental enhancers in humans. Nature 470(7333):279–283.
9. May D, et al. (2012) Large-scale discovery of enhancers from human heart tissue. Nat
Genet 44(1):89–93.
10. Wamstad JA, et al. (2012) Dynamic and coordinated epigenetic regulation of de-
velopmental transitions in the cardiac lineage. Cell 151(1):206–220.
11. Chang S, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart
to a subset of stress signals and play redundant roles in heart development. Mol Cell
Biol 24(19):8467–8476.
12. Zhang CL, et al. (2002) Class II histone deacetylases act as signal-responsive repressors
of cardiac hypertrophy. Cell 110(4):479–488.
13. Zhang T, et al. (2007) CaMKIIdelta isoforms differentially affect calcium handling but
similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 282(48):
35078–35087.
14. Trivedi CM, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by
modulating Gsk3 beta activity. Nat Med 13(3):324–331.
15. Kemi OJ, et al. (2008) Activation or inactivation of cardiac Akt/mTOR signaling di-
verges physiological from pathological hypertrophy. J Cell Physiol 214(2):316–321.
16. Toischer K, et al. (2010) Differential cardiac remodeling in preload versus afterload.
Circulation 122(10):993–1003.
17. Dong X, et al. (2012) Modeling gene expression using chromatin features in various
cellular contexts. Genome Biol 13(9):R53.
18. Feng J, Liu T, Qin B, Zhang Y, Liu XS (2012) Identifying ChIP-seq enrichment using
MACS. Nat Protoc 7(9):1728–1740.
19. Zang C, et al. (2009) A clustering approach for identiﬁcation of enriched domains
from histone modiﬁcation ChIP-Seq data. Bioinformatics 25(15):1952–1958.
20. Ross-Innes CS, et al. (2012) Differential oestrogen receptor binding is associated with
clinical outcome in breast cancer. Nature 481(7381):389–393.
21. McLean CY, et al. (2010) GREAT improves functional interpretation of cis-regulatory
regions. Nat Biotechnol 28(5):495–501.
22. Cheng C, et al. (2011) A statistical framework for modeling gene expression using
chromatin features and application to modENCODE datasets. Genome Biol 12(2):R15.
23. Turner BM (2007) Deﬁning an epigenetic code. Nat Cell Biol 9(1):2–6.
24. Creyghton MP, et al. (2010) Histone H3K27ac separates active from poised enhancers
and predicts developmental state. Proc Natl Acad Sci USA 107(50):21931–21936.
25. Zentner GE, Tesar PJ, Scacheri PC (2011) Epigenetic signatures distinguish multiple
classes of enhancers with distinct cellular functions. Genome Res 21(8):1273–1283.
26. Blow MJ, et al. (2010) ChIP-Seq identiﬁcation of weakly conserved heart enhancers.
Nat Genet 42(9):806–810.
27. Heinz S, et al. (2010) Simple combinations of lineage-determining transcription fac-
tors prime cis-regulatory elements required for macrophage and B cell identities.Mol
Cell 38(4):576–589.
28. Xu J, et al. (2006) Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy
in transgenic mice. J Biol Chem 281(14):9152–9162.
29. Miyamoto S, et al. (2006) Histone acetyltransferase activity of p300 is required for the
promotion of left ventricular remodeling after myocardial infarction in adult mice in
vivo. Circulation 113(5):679–690.
30. Hang CT, et al. (2010) Chromatin regulation by Brg1 underlies heart muscle de-
velopment and disease. Nature 466(7302):62–67.
31. Kaneda R, et al. (2009) Genome-wide histone methylation proﬁle for heart failure.
Genes Cells 14(1):69–77.
32. Stein AB, et al. (2011) Loss of H3K4 methylation destabilizes gene expression patterns
and physiological functions in adult murine cardiomyocytes. J Clin Invest 121(7):
2641–2650.
33. Rockman HA, et al. (1991) Segregation of atrial-speciﬁc and inducible expression of
an atrial natriuretic factor transgene in an in vivo murine model of cardiac hyper-
trophy. Proc Natl Acad Sci USA 88(18):8277–8281.
34. Peters AH, et al. (2003) Partitioning and plasticity of repressive histone methylation
states in mammalian chromatin. Mol Cell 12(6):1577–1589.
35. Thomas-Chollier M, et al. (2012) A complete workﬂow for the analysis of full-size
ChIP-seq (and similar) data sets using peak-motifs. Nat Protoc 7(8):1551–1568.
36. Trapnell C, et al. (2010) Transcript assembly and quantiﬁcation by RNA-Seq reveals
unannotated transcripts and isoform switching during cell differentiation. Nat
Biotechnol 28(5):511–515.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1315155110 Papait et al.
